Psoriasis drug trial for sensitive areas halted early

NCT ID NCT06042920

Terminated Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Deucravacitinib (SOTYKTU)
What this could lead to: If successful, this could provide a new treatment option for hard-to-treat psoriasis on the palms, soles, and genitals.
What could go wrong: The study was terminated early, so results are limited. As a phase 4 trial, safety and efficacy data may not be fully conclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENITAL PSORIASIS PALMOPLANTAR PSORIASIS

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Winston-Salem, North Carolina, 27157, United States
Local Institution - 0002

New York, New York, 10003, United States
Local Institution - 0004

Santa Monica, California, 90404, United States
Local Institution - 0005

East Windsor, New Jersey, 08520-2505, United States
Local Institution - 0007

Norfolk, Virginia, 23502-3933, United States
Local Institution - 0008

New York, New York, 10075, United States
Local Institution - 0009

Los Angeles, California, 90045-3606, United States
Local Institution - 0010

Houston, Texas, 77004, United States
Local Institution - 0012

Detroit, Michigan, 48202-3141, United States
Local Institution - 0015

Fountain Valley, California, 92708, United States
Local Institution - 0029

Rockville, Maryland, 20850-6243, United States
Local Institution - 0033

Mill Creek, Washington, 98012-1797, United States
Local Institution - 0034

Ciudad Autonoma Buenos Aires, C, C1425DKG, Argentina
Local Institution - 0037

Ciudad Autónoma Buenos Aires, B, C1428DZF, Argentina
Local Institution - 0042

Rosario, S, 2000, Argentina
Local Institution - 0043

Ciudad Autónoma Buenos Aires, B, 1425, Argentina
Local Institution - 0050

Phoenix, Arizona, 85006-2722, United States
Local Institution - 0052

Indianapolis, Indiana, 46250, United States
Local Institution - 0053

Plainfield, Indiana, 46168-2792, United States
Local Institution - 0054

Montreal, Quebec, H2X 2V1, Canada
Local Institution - 0055

Mayfield Heights, Ohio, 44124-4005, United States
Local Institution - 0056

Pittsburgh, Pennsylvania, 15213-3403, United States
Local Institution - 0057

Skokie, Illinois, 60077-1049, United States
Local Institution - 0058

Newmarket, Ontario, L3Y 5G8, Canada
Local Institution - 0059

Québec, Quebec, G1W 4R4, Canada
Local Institution - 0060

Toronto, Ontario, M3B 0A7, Canada
Local Institution - 0061

Saint-Jérôme, Quebec, J7Z 7E2, Canada
Local Institution - 0062

New York, New York, 10128, United States
Local Institution - 0064

Saskatoon, Saskatchewan, S7K 2C1, Canada
Local Institution - 0065

Montreal, Quebec, H1Y 3L1, Canada
Local Institution - 0066

Boardman, Ohio, 44512, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.